Effects of vaccination against bluetongue on milk production and quality in cattle vaccinated with live-attenuated monovalent type 2 vaccine.
The first epidemic of bluetongue (BT) to affect the three regions of Sardinia, Sicily and Calabria (Italy) in 2000 induced high economic losses caused by the disease itself and by the cessation of ruminant movements both within, and out of, the infected areas. In order to reduce virus circulation, and to create a resistant livestock population, the Italian Ministry of Health ruled, in May 2001, that all sheep, cattle, goats and water buffalo, in infected and in neighbouring regions, be vaccinated. The live-attenuated BTV-2 monovalent vaccine produced by Onderstepoort Biological Products in South Africa was to be used. Accordingly, in 2002, 98.6% of the sheep and goats, and 88.1% of the cattle, on Sardinia were vaccinated. Included was the vaccination of >70% of the cattle in the province of Oristano where >18,000 dairy cows in >220 herds are concentrated in the municipality of Arborea (Oristano) and which account for 65-70% of the milk produced in Sardinia. Using data collected at the centralised dairy co-operative since 1999 the quantity and quality of milk produced before vaccination against bluetongue was compared to that produced after vaccination. The following variables were analysed: average milk production/cow/month, monthly average fat content (%), monthly average protein content (%), average monthly somatic cell count and average monthly platelet count. The findings indicate that vaccination against BTV-2 in Sardinian dairy cattle did not impact negatively upon milk quantity nor milk quality.